PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2003 June; 4(2): 75–82.
Published online 2003 April 14. doi:  10.1208/pt040221
PMCID: PMC2750599

Kinetics of paclitaxel 2′-N-methylpyridinium mesylate decomposition

Abstract

This study was designed to examine the kinetics of decomposition of paclitaxel 2′-N-methylpyridinium mesylate (PNMM), a derivative of paclitaxel. Further, the potential for PNMM to act as a prodrug of paclitaxel was assessed in vitro. Stability studies of PNMM were conducted over a pH range of 4.0 to 8.0 at 25°C. The critical micelle concentration (CMC) of PNMM was determined by pulsating bubble surfactometry. Studies of the conversion of PNMM to paclitaxel were conducted in vitro in human plasma. Decomposition of PNMM followed apparent zero-order kinetics. The pH-rate profile exhibited no evidence of acid catalysis down to pH 4.0, while the rate was accelerated under base conditions. Surface tension studies suggested that PNMM formed micelles with a CMC of approximately 34 μg/mL. Conversion studies in phosphate buffer showed that no more than 5% of PNMM converted to paclitaxel, while in human plasma the conversion was about 25%. The degradation of PNMM was via apparent zero-order kinetics and was dependent upon pH. The observed apparent zero-order kinetics of decomposition of PNMM was consistent with the formation of micelles in phosphate buffer. In buffered aqueous media alone or in human plasma, PNMM did not convert quantitatively to paclitaxel. Thus, the limiting factor in the application of PNMM as a prodrug would appear to be the poor potential to convert to paclitaxel.

Keywords: prodrug, conversion, stability, solubility, micelle

Full Text

The Full Text of this article is available as a PDF (268K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Wani M, Taylor H, Wells M, Coggan P, McPhail A. Plant antitumor agent, VI: the isolation and structure of taxol, a novel antileukemic and antitumor agent from taxus brevifolia. J Am Chem Soc. 1971;93:2325–2327. doi: 10.1021/ja00738a045. [PubMed] [Cross Ref]
2. Markman M. Taxol: an important new drug in the management of ovarian cancer. Yale J Biol Med. 1991;64:583–590. [PMC free article] [PubMed]
3. McGuire W, Rowinsky E, Rosenheim N. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasm. Ann Intern Med. 1991;111:273–279. [PubMed]
4. Taxol NSC 125973 [Clinical Brochure] Bethesda, MD: National Cancer Institute; 1983.
5. Weiss R, Donehower R, Wiernik P, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8:1263–1268. [PubMed]
6. Nicolaou K, Guy R, Pitsinos E, Wrasidlo W. A water soluble prodrug of taxol with self-assembling properties. Angew Chem Int Ed Engl. 1994;34:1583–1587. doi: 10.1002/anie.199415831. [Cross Ref]
7. Deutsch H, Glinski J, Hernandez L. Synthesis of congeners and prodrugs. 3. Water soluble prodrugs of paclitaxel with potent antitumor activity. J Med Chem. 1989;32:788–792. doi: 10.1021/jm00124a011. [PubMed] [Cross Ref]
8. Zhao Z, Kingston D. Modified Taxols. 6. Preparation of water-soluble prodrugs of taxol. J Nat Prod. 1991;54:1607–1611. doi: 10.1021/np50078a018. [Cross Ref]
9. Vyas D, Wong H, Crosswell A. Synthesis and antitumor evaluation of water soluble taxol phosphates. Bioorg Med Chem Lett. 1993;3:1357–1360. doi: 10.1016/S0960-894X(00)80348-0. [Cross Ref]
10. Magri N, Kingston D. Modified taxols. 4. Synthesis and biological activity of taxols modified in the side chain. J Nat Prod. 1988;51:298–306. doi: 10.1021/np50056a017. [PubMed] [Cross Ref]
11. Feng X, Yuan Y-J, Wu J-C. Synthesis and evaluation of water-soluble paclitaxel prodrugs. Bioorg Med Chem Lett. 2002;12:3301–3303. doi: 10.1016/S0960-894X(02)00694-7. [PubMed] [Cross Ref]
12. Zhang X, Jaacson J, Burt H. Development of amphiphilic diblock copolymers as micellar carriers of taxol. Int J Pharm. 1996;132:195–206. doi: 10.1016/0378-5173(95)04386-1. [Cross Ref]
13. Qasem J. The Role of Counter-Ions in the Stability of N-methylpyridinium Prodrugs: A Case Study With N-methylpyridinium Prodrugs of Paclitaxel. Lexington, KY: University of Kentucky; 1999.
14. Engel GL, Farid NA, Faul MM, Richardson LA, Winneroski LL. Salt form selection and characterization of LY333531 mesylate monohydrate. Int J Pharm. 2000;198:239–247. doi: 10.1016/S0378-5173(00)00350-1. [PubMed] [Cross Ref]
15. Connors K, Amidon G, Kennon L. Chemical Stability of Pharmaceuticals. New York, NY: John Wiley & Sons; 1979. pp. 10–17.
16. Hiemenz P. Principles of Colloid and Surface Chemistry. New York, NY: Marcel Dekker Inc; 1977. pp. 100–105.

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists